CALIFORNIA (AP) — The U.S. Food and Drug Administration has approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given through an IV for patients needing hospitalization.
Join our WhatsApp groupSubscribe to our Daily Roundup Email
The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health.
It had been authorized for use on an emergency basis since spring, and now has become the first drug to win full U.S. approval for treating COVID-19.
Gilead says Veklury is approved for people at least 12 years old and weighing at least 88 pounds (40 kilograms) who need hospitalization for their coronavirus infection. It works by inhibiting a substance the virus uses to make copies of itself.
HCQ plus Zinc (Taken early stage) does the same thing.
The evidence is overwhelming (if one takes the time to research, and checks failed reports if it was done properly.)
I too am personally a beneficiary of Doc Zelenko’s protocol, Baruch Hashem.
And after months of research and interviews, i have not yet found a single case or incident where Hydroxychloroquine plus Zinc, failed (when taken within the first week of symptoms.)
My research included many dozens of reports and many thousands of patients. Globally.
So bottom line:
Remdesivir is the (less reliable and somewhat more dangerous) backup plan for those that missed the boat with (consistently successful) Hydroxy.
And only a $15,000 difference in the price-tag!
(Not to mention much more than that in hospital costs… and suffering….)
In other words, Trump is the winner of tonights debate
One more reason not to have a vaccine. There are numerous other treatments available as well. Each for different stages of the illness. The idea of universal vaccination for an illness that has a mortality rate of 0.001% and overwhelmingly kills those over 70 is insane. The only reason for such an action is to pour Billions of Dollars into the pockets of those who own pharmaceutical companies.